Cel-Sci (NYSEAMERICAN:CVM) Releases Earnings Results

Cel-Sci (NYSEAMERICAN:CVM) issued its quarterly earnings data on Friday. The company reported ($0.67) earnings per share (EPS) for the quarter, FiscalAI reports.

Cel-Sci Stock Up 10.0%

Shares of NYSEAMERICAN:CVM opened at $1.43 on Friday. The business has a 50-day moving average price of $3.29 and a 200 day moving average price of $4.92. The company has a current ratio of 1.39, a quick ratio of 1.35 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $12.14 million, a price-to-earnings ratio of -0.15 and a beta of 0.70. Cel-Sci has a 12-month low of $0.89 and a 12-month high of $13.48.

Institutional Trading of Cel-Sci

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its position in shares of Cel-Sci by 133.0% during the 1st quarter. Renaissance Technologies LLC now owns 35,890 shares of the company’s stock worth $115,000 after purchasing an additional 20,484 shares during the last quarter. XTX Topco Ltd acquired a new stake in shares of Cel-Sci during the 4th quarter worth about $66,000. State Street Corp increased its position in shares of Cel-Sci by 9.9% during the 4th quarter. State Street Corp now owns 25,570 shares of the company’s stock worth $134,000 after purchasing an additional 2,300 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Cel-Sci during the 4th quarter worth about $83,000. Finally, HRT Financial LP acquired a new stake in shares of Cel-Sci during the 4th quarter worth about $60,000. 12.08% of the stock is owned by institutional investors and hedge funds.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.